Increased free prostate specific antigen serum levels in Alzheimer's disease, correlation with Cognitive Decline

Zohara Sternberg, Rebecca Podolsky, Adam Nir, Jihnhee Yu, Raphael Nir, Stanley W. Halvorsen, Kailash Chadha, Joseph Quinn, Jeffrey Kaye, Channa Kolb

Research output: Contribution to journalArticle

Abstract

Background/aims: Prostate specific antigen (PSA) is regulated by steroid hormones, such as testosterone, the serum levels of which are altered in patients with Alzheimer's disease (AD).This pilot study compared serum levels of the free (f) PSA between AD, mild cognitive impairment (MCI), and control subjects, and evaluated the relationship between fPSA serum levels and cognitive assessment tests and neuroimaging data. In addition, in a subgroup of AD patients, we correlated fPSA serum levels with the existing data on serum levels of amyloid-beta (Aβ), and iron-related proteins, including hepcidin and ferritin. Methods: Frozen serum samples from the Oregon Tissue Bank were used to measure serum levels of fPSA using enzyme-linked immunosorbent assay. Results: fPSA serum levels calculated as median ± SD were higher in AD males (663.6 ± 821.0 pg/ml) compared to control males (152.0 ± 207.0 pg/ml), p = 0.003. A similar Pattern emerged when comparing MCI males (310.7 ± 367.0 pg/ml) to control males (P = 0.02). Correlation studies showed a significant association between fPSA and CDR (r = 0.56, P = 0.006) and CDR-SOB (r = 0.54, P = 0.009) in AD males. Conclusion: Additional studies in a larger cohort are required for determining whether fPSA can be used as biomarker of AD disease progression and whether it has the potential to identify male subjects at risk of AD dementia.

Original languageEnglish (US)
Pages (from-to)188-193
Number of pages6
JournalJournal of the neurological sciences
Volume400
DOIs
StatePublished - May 15 2019

Fingerprint

Prostate-Specific Antigen
Alzheimer Disease
Serum
Tissue Banks
Hepcidins
Cognitive Dysfunction
Ferritins
Amyloid
Neuroimaging
Disease Progression
Testosterone
Iron
Biomarkers
Enzyme-Linked Immunosorbent Assay
Steroids
Hormones

Keywords

  • ACT
  • Iron-related proteins
  • Mild cognitive impairment
  • Serum biomarker

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Increased free prostate specific antigen serum levels in Alzheimer's disease, correlation with Cognitive Decline. / Sternberg, Zohara; Podolsky, Rebecca; Nir, Adam; Yu, Jihnhee; Nir, Raphael; Halvorsen, Stanley W.; Chadha, Kailash; Quinn, Joseph; Kaye, Jeffrey; Kolb, Channa.

In: Journal of the neurological sciences, Vol. 400, 15.05.2019, p. 188-193.

Research output: Contribution to journalArticle

Sternberg, Zohara ; Podolsky, Rebecca ; Nir, Adam ; Yu, Jihnhee ; Nir, Raphael ; Halvorsen, Stanley W. ; Chadha, Kailash ; Quinn, Joseph ; Kaye, Jeffrey ; Kolb, Channa. / Increased free prostate specific antigen serum levels in Alzheimer's disease, correlation with Cognitive Decline. In: Journal of the neurological sciences. 2019 ; Vol. 400. pp. 188-193.
@article{5dae42a8bb46488e8f11de1f8d615cf9,
title = "Increased free prostate specific antigen serum levels in Alzheimer's disease, correlation with Cognitive Decline",
abstract = "Background/aims: Prostate specific antigen (PSA) is regulated by steroid hormones, such as testosterone, the serum levels of which are altered in patients with Alzheimer's disease (AD).This pilot study compared serum levels of the free (f) PSA between AD, mild cognitive impairment (MCI), and control subjects, and evaluated the relationship between fPSA serum levels and cognitive assessment tests and neuroimaging data. In addition, in a subgroup of AD patients, we correlated fPSA serum levels with the existing data on serum levels of amyloid-beta (Aβ), and iron-related proteins, including hepcidin and ferritin. Methods: Frozen serum samples from the Oregon Tissue Bank were used to measure serum levels of fPSA using enzyme-linked immunosorbent assay. Results: fPSA serum levels calculated as median ± SD were higher in AD males (663.6 ± 821.0 pg/ml) compared to control males (152.0 ± 207.0 pg/ml), p = 0.003. A similar Pattern emerged when comparing MCI males (310.7 ± 367.0 pg/ml) to control males (P = 0.02). Correlation studies showed a significant association between fPSA and CDR (r = 0.56, P = 0.006) and CDR-SOB (r = 0.54, P = 0.009) in AD males. Conclusion: Additional studies in a larger cohort are required for determining whether fPSA can be used as biomarker of AD disease progression and whether it has the potential to identify male subjects at risk of AD dementia.",
keywords = "ACT, Iron-related proteins, Mild cognitive impairment, Serum biomarker",
author = "Zohara Sternberg and Rebecca Podolsky and Adam Nir and Jihnhee Yu and Raphael Nir and Halvorsen, {Stanley W.} and Kailash Chadha and Joseph Quinn and Jeffrey Kaye and Channa Kolb",
year = "2019",
month = "5",
day = "15",
doi = "10.1016/j.jns.2019.04.006",
language = "English (US)",
volume = "400",
pages = "188--193",
journal = "Journal of the Neurological Sciences",
issn = "0022-510X",
publisher = "Elsevier",

}

TY - JOUR

T1 - Increased free prostate specific antigen serum levels in Alzheimer's disease, correlation with Cognitive Decline

AU - Sternberg, Zohara

AU - Podolsky, Rebecca

AU - Nir, Adam

AU - Yu, Jihnhee

AU - Nir, Raphael

AU - Halvorsen, Stanley W.

AU - Chadha, Kailash

AU - Quinn, Joseph

AU - Kaye, Jeffrey

AU - Kolb, Channa

PY - 2019/5/15

Y1 - 2019/5/15

N2 - Background/aims: Prostate specific antigen (PSA) is regulated by steroid hormones, such as testosterone, the serum levels of which are altered in patients with Alzheimer's disease (AD).This pilot study compared serum levels of the free (f) PSA between AD, mild cognitive impairment (MCI), and control subjects, and evaluated the relationship between fPSA serum levels and cognitive assessment tests and neuroimaging data. In addition, in a subgroup of AD patients, we correlated fPSA serum levels with the existing data on serum levels of amyloid-beta (Aβ), and iron-related proteins, including hepcidin and ferritin. Methods: Frozen serum samples from the Oregon Tissue Bank were used to measure serum levels of fPSA using enzyme-linked immunosorbent assay. Results: fPSA serum levels calculated as median ± SD were higher in AD males (663.6 ± 821.0 pg/ml) compared to control males (152.0 ± 207.0 pg/ml), p = 0.003. A similar Pattern emerged when comparing MCI males (310.7 ± 367.0 pg/ml) to control males (P = 0.02). Correlation studies showed a significant association between fPSA and CDR (r = 0.56, P = 0.006) and CDR-SOB (r = 0.54, P = 0.009) in AD males. Conclusion: Additional studies in a larger cohort are required for determining whether fPSA can be used as biomarker of AD disease progression and whether it has the potential to identify male subjects at risk of AD dementia.

AB - Background/aims: Prostate specific antigen (PSA) is regulated by steroid hormones, such as testosterone, the serum levels of which are altered in patients with Alzheimer's disease (AD).This pilot study compared serum levels of the free (f) PSA between AD, mild cognitive impairment (MCI), and control subjects, and evaluated the relationship between fPSA serum levels and cognitive assessment tests and neuroimaging data. In addition, in a subgroup of AD patients, we correlated fPSA serum levels with the existing data on serum levels of amyloid-beta (Aβ), and iron-related proteins, including hepcidin and ferritin. Methods: Frozen serum samples from the Oregon Tissue Bank were used to measure serum levels of fPSA using enzyme-linked immunosorbent assay. Results: fPSA serum levels calculated as median ± SD were higher in AD males (663.6 ± 821.0 pg/ml) compared to control males (152.0 ± 207.0 pg/ml), p = 0.003. A similar Pattern emerged when comparing MCI males (310.7 ± 367.0 pg/ml) to control males (P = 0.02). Correlation studies showed a significant association between fPSA and CDR (r = 0.56, P = 0.006) and CDR-SOB (r = 0.54, P = 0.009) in AD males. Conclusion: Additional studies in a larger cohort are required for determining whether fPSA can be used as biomarker of AD disease progression and whether it has the potential to identify male subjects at risk of AD dementia.

KW - ACT

KW - Iron-related proteins

KW - Mild cognitive impairment

KW - Serum biomarker

UR - http://www.scopus.com/inward/record.url?scp=85064039354&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064039354&partnerID=8YFLogxK

U2 - 10.1016/j.jns.2019.04.006

DO - 10.1016/j.jns.2019.04.006

M3 - Article

VL - 400

SP - 188

EP - 193

JO - Journal of the Neurological Sciences

JF - Journal of the Neurological Sciences

SN - 0022-510X

ER -